HealthUSA

4 countries approved the testing of vaccines against coronavirus in humans

In an attempt to stop the spread of a new coronavirus, a number of countries have already approved the testing of vaccines on humans.

As of Wednesday, April 22, the new coronavirus that causes respiratory disease COVID-19, struck more than 2.5 million people worldwide. According to the tracker at the Johns Hopkins University, at least 179 of 725 people have died.

On Wednesday, Germany became the fourth country to approve trials of a vaccine against COVID-19 people.

The Paul Ehrlich Institute (The Paul Ehrlich Institute), the regulatory body of Germany for vaccines approved for human testing of the vaccine, developed by local firm BioNTech and pharmaceutical company Pfizer USA.

“Given the serious consequences of the pandemic COVID-19, this is a significant step towards the development of effective and safe vaccines”, – reads the statement of the Paul Ehrlich Institute.

Clinical trials will be conducted in 200 healthy volunteers aged 18 to 55 years. If the vaccine shows positive results, further tests will be carried out on people with a higher risk of infection.

The vaccine trials on humans has also been recently approved in the United Kingdom. According to the Minister of health of great Britain Matt Hancock, the vaccine, developed at Oxford University, should begin testing on humans as early as Thursday, and another vaccine developed by Imperial College (Imperial College), will begin recruitment of volunteers by June.

Vaccine trials on humans were also previously approved in the United States and China. In the US, a vaccine was developed by Inovio Pharmaceuticals and expects test results by the end of summer. Other developed Moderna Inc. in March.

In China two experimental vaccines against COVID-19 has been approved for human trials. According to Reuters, vaccines are developed by Beijing Sinovac Biotech company, and Wuhan Institute of biological products.

Source:

usa.one

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close

Please disable your ad blocker

We know you are here for the stories. Not the ads. But we need the ads to keep the lights on. So please whitelist Buzzon.live.